切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2019, Vol. 08 ›› Issue (03) : 238 -241. doi: 10.3877/cma.j.issn.2095-3232.2019.03.014

所属专题: 文献

临床研究

肝癌合并门静脉癌栓术前放疗疗效评价
冯爽1, 李铁华1, 孙居仙1, 徐胜1, 李晶1, 陆艳1, 孟岩1,()   
  1. 1. 200438 上海,第二军医大学东方肝胆外科医院放射治疗科
  • 收稿日期:2019-02-28 出版日期:2019-06-10
  • 通信作者: 孟岩
  • 基金资助:
    上海市卫计委科研课题面上项目(201740249)

Evaluation of clinical efficacy of preoperative radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus

Shuang Feng1, Tiehua Li1, Juxian Sun1, Sheng Xu1, Jing Li1, Yan Lu1, Yan Meng1,()   

  1. 1. Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
  • Received:2019-02-28 Published:2019-06-10
  • Corresponding author: Yan Meng
  • About author:
    Corresponding author: Meng Yan, Email:
引用本文:

冯爽, 李铁华, 孙居仙, 徐胜, 李晶, 陆艳, 孟岩. 肝癌合并门静脉癌栓术前放疗疗效评价[J]. 中华肝脏外科手术学电子杂志, 2019, 08(03): 238-241.

Shuang Feng, Tiehua Li, Juxian Sun, Sheng Xu, Jing Li, Yan Lu, Yan Meng. Evaluation of clinical efficacy of preoperative radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2019, 08(03): 238-241.

目的

探讨术前放疗对原发性肝癌(肝癌)伴门静脉癌栓的疗效及其应用价值。

方法

回顾性分析2014年1月至2017年12月东方肝胆外科医院收治的248例肝癌合并门静脉癌栓患者临床资料。其中男189例,女59例;年龄32~82岁,中位年龄53岁。患者均签署知情同意书,符合医学伦理学规定。根据治疗方法不同患者分为术前放疗+手术组(术前放疗组,102例)和单纯放疗组(146例)。观察放疗效果和不良反应。生存分析采用非参数法Wilcoxon检验。

结果

多数患者放疗期间有不同程度的消化道反应,表现为恶心、呕吐、纳差、腹胀等,未见上消化道出血及严重呕吐,均经对症治疗后缓解。患者均未发生严重的肝损害。通过术前18 Gy剂量放疗,最终41%(102/248)患者获得手术机会。放疗后肿瘤大面积坏死,门静脉癌栓局限、硬化、纤维化。术前放疗组1年生存率为49%,明显高于单纯放疗组的32%(Z=44.804,P<0.05)。

结论

术前放疗可使部分肝癌合并门静脉癌栓患者降期,获得手术切除机会,明显改善患者预后,延长总体生存时间。

Objective

To evaluate the clinical efficacy and application value of preoperative radiotherapy for primary liver cancer (PLC) complicated with portal vein tumor thrombus.

Methods

Clinical data of 248 patients with PLC complicated with portal vein tumor thrombus admitted to Eastern Hepatobiliary Surgery Hospital from January 2014 to December 2017 were retrospectively analyzed. Among them, 189 patients were male and 59 female, aged 32-82 years with a median age of 53 years. The informed consents of all patients were obtained and the local ethical committee approval was received. All patients were divided into preoperative radiotherapy + surgery group (preoperative radiotherapy group, n=102) and single radiotherapy group (n=146). The clinical efficacy and safety of radiotherapy were evaluated. Survival analysis was performed by nonparametric Wilcoxon test.

Results

During the period of receiving radiotherapy, most patients suffered from varying degrees of digestive tract reactions, such as nausea, vomiting, anorexia and abdominal distension, etc. No upper gastrointestinal hemorrhage or severe vomiting were observed. All symptoms were relieved after symptomatic treatments. No severe liver damage occurred in any patient. After preoperative radiotherapy at a dose of 18 Gy, 41% (102/248) of the patients obtained the opportunity of undergoing surgery. After radiotherapy, extensive tumor necrosis was observed, portal vein tumor thrombus became localized, hardened and fibrotic. In the preoperative radiotherapy group, the 1-year survival rate was 49%, significantly higher than 32% in single radiotherapy group (Z=44.804, P<0.05).

Conclusions

Preoperative radiotherapy can reduce the staging of liver cancer patients complicated with portal vein tumor thrombus and obtain the opportunity of surgical resection, which can significantly improve the clinical prognosis and prolongs the overall survival of patients.

图1 一例单纯放疗组肝癌合并门静脉癌栓患者放疗疗效观察
图2 一例术前放疗组肝癌合并门静脉癌栓患者术后病理切片
[1]
李斌,肖平,卢景琛.多学科协作诊治策略指导下的肿瘤学临床教学模式构建[J].卫生职业教育,2014, 32(13):47-48.
[2]
Jemal A,Bray F,Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[3]
邹燕梅,熊华,胡广原,等.尝试PBL与肿瘤MDT及个体化治疗相结合的教学模式[J].中国医学创新,2013, 10(24):79-81.
[4]
周俭,肖永胜,樊嘉.肝癌合并门静脉癌栓的研究进展[J].中国普外基础与临床杂志,2012, 19(3):243-246.
[5]
Peng BG,He Q,Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009, 198(3):313-318.
[6]
Yamada K,Lzaki K,Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 57(1):113-119.
[7]
Catalano OA,Choy G,Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging[J]. Radiology, 2010, 254(1):154-162.
[8]
Ferlay J,Soerjomataram I,Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5):E359-386.
[9]
Cheung TK,Lai CL,Wong BC, et al. Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong[J]. Aliment Pharmacol Ther, 2006, 24(4): 573-583.
[10]
Minagawa M,Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus[J]. World J Gastroenterol, 2006, 12(47):7561-7567.
[11]
Llovet JM,Bustamante J,Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999, 29(1):62-67.
[12]
Zeng ZC,Tang ZY,Fan J, et al. Consideration of the role of radiotherapy for lymph node metastases in patients with HCC-a retrospective analysis for prognostic factors from 125 patients[J]. Int J Radiation Oncology Boil Phys, 2005, 63(4):1067-1076.
[13]
Hou JZ,Zeng ZC,Wang BL, et al. High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT[J]. Jpn J Clin Oncol, 2016, 46(4):357-362.
[14]
Nakazawa T,Hidaka H,Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis[J]. BMC Gastroenterol, 2014(14):84.
[15]
Kodama K,Kawaoka T,Aikata H, et al. Comparison of outcome of hepatic arterial infusion chemotherapy combined with radiotherapy and sorafenib for advanced hepatocellular carcinoma patients with major portal vein tumor thrombosis[J]. Oncology, 2018, 94(4):215-222.
[16]
Wang K,Guo WX,Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis[J]. Medicine, 2016, 95(11):e3015.
[17]
Kim GA,Shim JH,Yoon SM, et al. Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis[J]. J Vasc Interv Radiol, 2015, 26(3):320-329, e6.
[18]
Lu DH,Fei ZL,Zhou JP, et al. A comparison between three-dimensional conformal radiotherapy combined with interventional treatment and interventional treatment alone for hepatocellular carcinoma with portal vein tumour thrombosis[J]. J Med Imaging Radiat Oncol, 2015, 59(1):109-114.
[19]
Park MS,Kim SU,Park JY, et al. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis[J]. Cancer Chemother Pharmacol, 2013, 71(1): 165-173.
[20]
Yoon SM,Ryoo BY,Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial[J]. JAMA Oncol, 2018, 4(5):661-669.
[1] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[2] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[3] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[4] 陈亚峰, 李江斌, 王栋, 臧莉, 鲁建国, 董瑞. 腹腔镜脾切除术在巨脾脾动脉栓塞后远期治疗中的应用[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 571-574.
[5] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[6] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[7] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[8] 严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[9] 张文华, 陶焠, 胡添松. 不同部位外生型肝癌临床病理特点及其对术后肝内复发和预后影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 651-655.
[10] 韩宇, 张武, 李安琪, 陈文颖, 谢斯栋. MRI肝脏影像报告和数据系统对非肝硬化乙肝患者肝细胞癌的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 669-673.
[11] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[12] 张维志, 刘连新. 基于生物信息学分析IPO7在肝癌中的表达及意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 694-701.
[13] 陈安, 冯娟, 杨振宇, 杜锡林, 柏强善, 阴继凯, 臧莉, 鲁建国. 基于生物信息学分析CCN4在肝细胞癌中表达及其临床意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 702-707.
[14] 叶文涛, 吴忠均, 廖锐. 癌旁组织ALOX15表达与肝癌根治性切除术后预后的关系[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 708-712.
[15] 吴晨瑞, 廖锐, 贺强, 潘龙, 黄平, 曹洪祥, 赵益, 王永琛, 黄俊杰, 孙睿锐. MDT模式下肝动脉灌注化疗联合免疫靶向治疗肝细胞癌多处转移一例[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 713-716.
阅读次数
全文


摘要